



MINISTERIO  
DE SANIDAD, CONSUMO  
Y BIENESTAR SOCIAL



agencia española de  
medicamentos y  
productos sanitarios

DEPARTAMENTO DE  
MEDICAMENTOS  
VETERINARIOS

# Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8  
28022 – Madrid  
España  
(Reference Member State)

ES/V/0292/001/DC

## PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

**Hedylon 5 mg tablets for dogs and cats**

CORREO ELECTRÓNICO

[mresvet@aemps.es](mailto:mresvet@aemps.es)

14693 PuAR HEDYLON 5 mg FINAL

F-DMV-25-05

C/ CAMPEZO, 1 – EDIFICIO 8  
28022 MADRID  
TEL: 91 822 54 01  
FAX: 91 822 5443



## MODULE 1

### PRODUCT SUMMARY

|  |  |
|--|--|
| EU Procedure number                    | ES/V/0292/001/DC   |
| Name, strength and pharmaceutical form | Hedylon 5 mg tablets for dogs and cats   |
| Applicant                              | LIVISTO Int'l, S.L.<br>Av. Universitat Autònoma, 29<br>08290 Cerdanyola del Vallès (Barcelona)<br>Spain              |
| Active substance(s)                    | Prednisolone   |
| ATC Vet code                           | QH02AB06   |
| Target species                         | Dogs and cats  |
| Indication for use                     | For the symptomatic treatment or as adjunct treatment of inflammatory and immune-mediated diseases in dogs and cats. |



## **MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (<http://www.hma.eu>).

## MODULE 3

### PUBLIC ASSESSMENT REPORT

|  |   |
|--|---|
| Legal basis of original application                                    | Generic application in accordance with Article 13.1 of Directive 2001/82/EC as amended. |
| Date of completion of the original decentralized procedure             | 21 Nov 2018   |
| Date product first authorised in the Reference Member State (MRP only) | NA  |
| Concerned Member States for original procedure                         | AT, CY, CZ, DK, EE, FR, DE, EL, HU, IE, IT, LV, LT, NL, PL, PT, RO, SK, SI.             |

#### I. SCIENTIFIC OVERVIEW

***For public assessment reports for the first authorisation in a range:***

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.



## II. QUALITY ASPECTS

### A. *Qualitative and quantitative particulars*

The product contains 5 mg/tablet of prednisolone and excipients lactose monohydrate, maize starch, pre-gelatinised starch, colloidal anhydrous silica, talc and magnesium stearate.

The container/closure system is PVC/Aluminium blister

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

### B. *Method of Preparation of the Product*

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### C. *Control of Starting Materials*

The active substance is prednisolone an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practices.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Certificate of suitability issued by the EDQM has been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

### D. *Control on intermediate products*

The tests performed during production are described and the results conforming to the specifications, are provided.

### E. *Control Tests on the Finished Product*



The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

#### **F. Stability**

The active substance is fully tested to ensure compliance with its specification immediately prior to its use in manufacture of the product.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

#### **G. Other Information**



### III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

**For generics, insert in the relevant sections as appropriate:**

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of safety tests are not required.

#### **III.A Safety Testing**

##### **Pharmacological Studies**

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of pharmacological studies are not required.

##### **Toxicological Studies**

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of toxicological studies are not required.

The safety aspects of this product are identical to the reference product

#### **User Safety**

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product:

- Prednisolone or other corticosteroids may cause hypersensitivity (allergic reactions).
- People with known hypersensitivity to prednisolone or other corticosteroids, or any of the excipients, should avoid contact with the veterinary medicinal product.
- To avoid accidental ingestion, particularly by a child, unused part-tablets should be returned to the open blister space and inserted back into the carton.
- In case of accidental ingestion, especially by a child, seek medical advice immediately and show the package leaflet or the label to the physician.
- Corticosteroids can cause foetal malformations; therefore it is recommended that pregnant women avoid contact with the veterinary medicinal product.
- Immediately wash hands thoroughly after handling the tablets.

#### **Environmental Risk Assessment**

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will only be used in non-food animals.

#### **III.B Residues documentation Not applicable**



#### **IV. CLINICAL ASSESSMENT (EFFICACY)**

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

##### ***IV.A Pre-Clinical Studies***

As this was a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, pre-clinical studies are not required.

##### ***IV.B Clinical Studies***

As this was a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, clinical studies are not required.





## V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

## MODULE 4

### POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website ([www.hma.eu](http://www.hma.eu)).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>

**or**

*Complete this section for extensions to the same VPA range or defined, significant variations, using the table shown below.*

*Some examples of significant changes in safety or efficacy data are:*

- *Changes to pharmacokinetic data leading to a change in the SPC*
- *Changes to toxicological data leading to a change in the SPC*
- *Changes to user safety warnings*
- *Changes to ecotoxicological information as given in the SPC or changes to disposal warnings*
- *New residue studies in new target species or tissues*
- *Reassessment of residue data or new studies resulting from changes to MRL*
- *Changes to withdrawal period*
- *Changes to target species*
- *Changes to target species tolerance data leading to change in warnings/precautions for target species*
- *New or changed indications*

*Significant changes in administrative or quality data include any Type II change, which affects the initial report. The following Type IA or IB changes may also apply:*

- *Name of product [Type IA: 2]*
- *Name of active substance [Type IA: 3]*
- *MAH [Type IA: 1]*
- *Composition of the medicinal product [Type IB: 18, Type IA/B: 25, 34, 35, 39]*
- *Container/closure system [Type 1/B: 26, 28, 29, 36, 41, 43]*
- *Method of preparation [Type 1B: 33]*
- *Active substance specification [Type IB: 25]*
- *CEP [Type IA/B: 15]*
- *Re-test period or storage conditions of active substance [Type IB: 17]*
- *Excipient specifications [Type 1A/B: 25]*
- *Packaging materials [Type 1A/B: 28, 29, 36, 41, 43]*
- *TSE [Type 1A: 16, 22]*

- *Shelf-life or storage conditions of the finished product [Type 1B: 42]*

### Quality changes

| Summary of change<br>(Application number)                                 | Section updated in<br>Module 3 | Approval date |
|---|--------------------------------|---------------|
| <Example: Change to active substance specification><br>(MS/V/XXX/X/IB/XX) | N/A                            |               |
|   |                                |               |
|   |                                |               |
|   |                                |               |

### Safety/efficacy changes

| Summary of change<br>(Type; application number)                    | Section updated in<br>Module 3 | Approval date |
|--|--------------------------------|---------------|
| <Example: Addition of target species - pigs><br>(MS/V/XXX/X/II/XX) | <IIIA><br><IIIB><br><IV>       |               |
|  |                                |               |
|  |                                |               |
|  |                                |               |